Genfit SA (GNFT) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genfit SA is making strides in their liver disease programs, with Ipsen set to present new data on elafibranor at The Liver Meeting 2024 and positive commercial progress in the U.S. and Europe. The company is also advancing its Acute-on-Chronic Liver Failure (ACLF) program, with multiple clinical trials planned for 2025 and recent protocol improvements to enhance trial recruitment. These developments highlight Genfit’s commitment to expanding its presence in the liver health sector and improving patient outcomes.
For further insights into GNFT stock, check out TipRanks’ Stock Analysis page.
